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10Rationale and Objectives: This study is aimed at investigating neurochemical changes in scopolamine (SCP)–induced memory impair-
ment using spatially localized in vivo magnetic resonance spectroscopy (MRS) of the hippocampus.
Materials andMethods: Four groups of mice (eight mice per group) were scanned after the injection of different SCP doses: 0, 1, 3, and 5
mg/kg (intraperitoneally). All the animals received 1H MRS of their hippocampus at two time intervals: 30 minutes and 72 hours after SCP
injection.
Results: This work demonstrated that the doses of 3 mg/kg SCP or higher reduce the concentration of total choline–containing com-
pounds, and these levels returned to baseline after 72 hours. These results are consistent with observations made by others using
more invasive brain dialysis approaches. The levels of glutamate and glutamic compounds (glutamate + glutamine) were slightly changed
at 3 and 5 mg/kg SCP dose, but the differences were not statistically significant (P > .05). These findings suggest that SCP produces tran-
sient, in vivo measurable alterations in the cholinergic system in the hippocampus.
Conclusions: On this basis, we conclude that in vivoMRS is a feasible noninvasivemethod to probe aspects of the alterations induced by
SCP in the cholinergic neurotransmission pathways in both animal models and human studies of memory impairment.
Key Words: 1H MR spectroscopy; scopolamine; memory impairment; cholinergic system.
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holinergic deficiency in human brain is the most
severe and consistent biochemical change in mild
cognitive impairment (MCI) and Alzheimer disease
(AD) (1–3). This is seen as reduced levels of acetylcholine
(ACh), choline acetyltransferase, and acetylcholinesterase
reported in both necropsy brain samples and cerebrospinal
fluid. In general, animal models of memory impairment
have been used to understand the molecular basis of
cognitive decline and identify therapeutic targets.
Scopolamine (SCP), which is known as a muscarinic
cholinergic receptor antagonist, has been used to induce
memory deficit/amnesia such as is present in MCI and AD.
SCP inhibits central cholinergic neuronal activity and
impairs learning and short-term memory (4–7). Numerousad Radiol 2014; 21:1072–1077
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Open access under CC BY-NC-ND license.studies have tried to find treatments that attenuate the
effects of SCP-induced memory impairment (8–12). Several
studies reported that the mechanism of memory impairment
by cholinergic deficits may be through the modulation of
the cerebrovasculature (13–15) and decreased blood flow
and blood volume may induce rapid cognitive decline (16).
Although the precise molecular details and the influence of
SCP on neurometabolic pathways have not been completely
elucidated, SCP has been used widely to produce animal
models of memory impairment.
The development of spatially localized in vivo proton
magnetic resonance spectroscopy (1H MRS) of the brain has
led to both mechanistic studies of brain metabolism in animal
models of disease and numerous clinical studies of human
diseases and their progression (17,18). 1H MRS is well suited
for the study of cognitive disorders, because it is noninvasive,
reproducible, and can sample the in vivo metabolism of many
brain regions. At present, 20 compounds can be detected
on 3T and 7T whole body magnetic resonance (MR)
scanners. Some of these compounds are neurotransmitters
(19,20). In particular, a resonance reflecting a composite peak
representing total choline–containing compounds (tCho) is
one of important metabolites in 1H MRS studies of memory
Figure 1. Localized hippocampal region:
(a) axial and (b) sagittal view (voxel size:
1.5  2.0  2.5 mm) and magnetic reso-
nance spectra at 30 minutes after (c) 0,
(d) 1, (e) 3, and (f) 5 mg/kg scopolamine
dose.
Academic Radiology, Vol 21, No 8, August 2014 1H MRS IN MOUSE BRAIN POSTADMINISTRATION OF SCPimpairment. Some studies have reported that total choline
signal in 1H MRS has been changed in MCI and AD
patients (21,22). This total choline peak is made up of ACh,
glycerophosphocholine (GPC), phosphocholine (PC), and
free choline (23,24).
Until now, studies of the effect of SCPon the brain, primar-
ily memory impairment by cholinergic deficits, have been
evaluated by invasive methods, such as high-performance
liquid chromatography, and behavioral tests (4,25–29). To
date, there have been no reported noninvasive in vivo 1H
MRS studies aimed at determining any metabolic changes
in the brain as a result of SCP administration. In this study,
we report that noninvasive in vivo 1H MRS can detect
metabolic changes in SCP-induced memory impairment in
the brain of mice. We also show time- and dose-dependent
neurochemical changes induced by the administration of
SCP in this murine model.MATERIALS AND METHODS
Animals and Drugs
Adult male Swiss albino mice (12–16 weeks) weighing 25–30 g
(n = 32) were housed (four mice per cage) on sawdust and kept
on a 12/12 hours light–dark cycle, with free access to food and
water throughout the experiment. All the procedureswere per-
formed under an approved protocol by the Institutional Animal
Care and Use Committee of University of Texas Southwestern
Medical Center. All efforts were made tominimize the number
of animals used and their distress.
Scopolamine hydrobromide was obtained from the Sigma–
Aldrich Company, dissolved in 0.9% normal saline (0.2 mL)
and administered by intraperitoneal injection. Mice were
assigned to four groups according to doses: SCP 0, 1, 3, and 5
mg/kg. All the mice received 1H MRS as soon as they were
anesthetized at 30 minutes and 72 hours after SCP injection.Proton Magnetic Resonance Imaging/Magnetic
Resonance Spectroscopy
All the mice were anesthetized by spontaneous inhalation of
1.5%–2% isoflurane mixed in air and delivered via a mask
using an anesthesia unit to minimize the motion of the mouse
during MR scanning. The mice were placed in the handling
system in prone position, and a homemade surface coil (1-cm
diameter) was used to acquire signals. The animals breathed
freely during an hour of total MR acquisition and were
monitored for changes in the respiratory rate to adjust the
concentration of anesthetic.
All the MR studies were carried out in a horizontal 9.4T/
16 cm magnet (Agilent, Palo Alto, CA), with 400 mT/m
gradient sets. For localization and identification of the anatomic
landmarks, T2-weighted MR images (fast spin echo [FSE])
were acquired: repetition time (TR)/ echo time
(TE) = 3000/10 milliseconds, matrix size = 256  256, slice
thickness = 1.0 mm, NEX = 2, and 12 slices. The volume of
interest (VOI) was adjusted to include the left hippocampal
region. The size of VOI for MRS was 7.5 mL
(1.5 2.0 2.5mm3). A point-resolved spectroscopy sequence
was used to localize the VOIs: TR/TE = 3000/19milliseconds,
average = 512, complex data points = 4096, spectral
width = 4000 Hz. VAPOR-optimized pulse power and timing
was used to suppress the water signal. For quantification, the
unsuppressed water signals were also obtained (average = 4).
All the procedures for MR scanning (MRI + MRS) were
finished within 1 hour.
Quantification
All the in vivo 1H MR spectra were processed with the linear
combination analysis method (LCModel ver. 6.0; Los
Angeles, CA) to calculate metabolite concentrations from a
fit to the experimental spectrum, based on simulated basis set.
The following brain metabolites in the basis set were included:1073
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Figure 2. At 30 minutes after injection, total choline–containing
compounds (tCho) level decreased at 3 and 5 mg/kg comparing
with 0 and 1 mg/kg: mean  standard deviation, F(3,28) = 10.231,
P = .0001.
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1074alanine, aspartate, creatine (Cr), g-aminobutyric acid (GABA),
glucose, glutamate (Glu), glutamine (Gln), glycerophosphoryl-
choline (GPC), phosphorylcholine (PCh),myo-inositol (mIns),
lactate (Lac), phosphocreatine (PCr), N-acetylaspartate (NAA),
N-acetylaspartylglutamate (NAAG), phosphoethanolamine,
taurine (Tau), several macromolecules, and lipids. The analysis
was performed in the frequency domain between 0.2 and
4.3 ppm using water-suppressed raw data (FIDs). Absolute me-
tabolites concentrations were calculated using the unsuppressed
water signal as an internal reference (assuming 80% brain water
content).Analysis
The in vivo proton spectra were judged to of acceptable
quality if the signal-to-noise ratio (SNR) of the highest
peak (mostly, Cr) was 8 or more and the standard deviation
of the fit for the metabolite was <20%. All the data were
analyzed using IBM SPSS (Windows ver.20.0; Dublin,
Ireland). The data for each metabolite were tested for homo-
geneity of variance, and a one-way analysis of variance
followed by Tukey HSD (honest significance difference)
post hoc test was used to compare the means of the metabolite
concentrations among the four groups. P values <0.05 were
considered as statistically significant.RESULTS
FSE images provided the anatomic viewof themouse brain that
guaranteed precise placement of the VOI in the hippocampal
region (Fig 1). Also, Figure 1 shows representative spectra
obtained from hippocampus of each group at 30 minutes after
SCP injection. The acceptable SNR (>8) could be acquired
under the sharp unsuppressed water signal (<18 Hz line width)
after three-dimensional shimming. Our analysis focused on
Figure 3. The neurochemical profiles of (a) 0, (b) 1, (c) 3, and (d) 5 mg/kg scopolamine (SCP)–induced mouse brain (mmol, mean standard
deviation). In the 0 and 1 mg/kg SCP dose brains, there was no change between at 30 minutes and at 72 hours after injection. At 3 and 5 mg/kg
SCP dose, total choline–containing compounds level was recovered after 72 hours. *P = .024, **P = .015.
Academic Radiology, Vol 21, No 8, August 2014 1H MRS IN MOUSE BRAIN POSTADMINISTRATION OF SCPeight metabolites of the #20% Cramer–Rao lower bounds
(CRLBs) which are Gln, Glu, amino acid (Glx: Glu + Gln),
mIns, Tau, total creatine (tCr: PCr + Cr), total choline
(tCho: GPC + PCh + Cho + ACh), and total NAA (tNAA:
NAA + NAAG; Table 1).
Only differences in tCho at 30 minutes after SCP injection
reached the level of statistical significance. The tCho level at
3 and 5 mg/kg SCP dose was significantly reduced as
comparing with 0 and 1 mg/kg: F(3,28) = 10.231, P = .0001
(0 vs. 3 mg/kg: P0–3 = 0.003; 0 vs. 5 mg/kg: P0–5 = 0.001; 1
vs. 3 mg/kg: P1–3 = 0.007; and 1 vs. 5 mg/kg: P1–5 = 0.003;
Fig 2). There is no significant change in relationship to the
SCP dose in any of the other metabolites.
Figure 3 shows the concentrations (millimoles, wet weight)
of metabolites at each SCP doses and each time after admin-
istration. In the 0 and 1 mg/kg SCP dose groups, there was
no metabolite that was significantly changed between
30 minutes and 72 hours after injection. However, in 3 and
5 mg/kg SCP dose group, tCho level increased (P = .024 at
3 mg/kg and P = .015 at 5 mg/kg dose).DISCUSSION
SCP is a tropan alkaloid that has been reported to have a
variety of effects on the human brain including hallucinations
and amnesia. It has had a range of clinical uses including its use
as an obstetrical analgesic and the alleviation of motion sick-
ness. SCP, which is a nonselective muscanergic antagonist,became a popular agent for creating neuropharmacological
models in both human and animals based on the concept of
cholinergic blockade on human memory (30,31). For
example, Sunderland et al. (32,33) showed that patients with
AD have higher cognitive and behavioral sensitivity to SCP
(at doses of $0.5 mg/kg) than normal controls. Barker et al.
(34) showed that the cognitive sensitivity against SCP
increases with age in humans. Thus, the administration was
proposed as a diagnostic test for AD in humans (30).
The use of SCP in animal models of cognitive impairment
was recently reviewed by Klinkenberg and Blokland (31).
Based on this exhaustive review, the authors concluded that
the cognitive effects observed after the systemic administra-
tion of SCP are caused by nonselective inhibition of central
choline signaling. The role of ACh in both learning and reten-
tion has been an active area for research. Hasselmo and
McGaughy (35) have described a model for memory encod-
ing and retrieval in which high levels of ACh enable the
encoding of new information, whereas low levels of ACh
promote the recall of previously stored memories. Animal
studies exploring this model have involved using a variety of
tests directed at memory and learning performance in rodents
(31). In some of these tests, the dose and time of injection of
SCP were varied to attempt to separate the effects of SCP on
these two different behavioral processes. As pointed out in
the review by Klinkenberg and Blokland (31), a dose of
0.1 mg/kg of SCP or higher should be considered as a high
dose in rodent models.1075
WOO AND LENKINSKI Academic Radiology, Vol 21, No 8, August 2014Perhaps more relevant to our study is the report of Toide
(36) that showed the effects of systemic injection of SCP
(0.5 mg/Kg) on the levels of ACh and choline in the hippo-
campus of freely moving rats using dialysis. The levels of
ACh increased and choline decreased (by about a factor of
two) 45 minutes after injection and both ACh and choline
levels returned to normal after 3 hours. Similar increases in
ACh have been reported for other brain regions (nucleus
accumbens and neostriatum) also using brain dialysis in freely
moving rats after the systemic injection of 0.5 mg/kg of SCP.
As pointed out in the introduction, the availability of spatially
localized in vivo 1H MRS provides a means for interrogating
different regions of the brain in both human and animals. In
this study, we chose to focus on metabolic alterations induced
by SCP in the hippocampus, because this region has been
accepted to play an important role in working memory.
This was the only region studied since after injection of
SCP, because it took about 2 hours to acquire interpretable
MR spectra. The preparation time (30 minutes for free
exploring + 30 minutes for anesthesia and animal positioning)
was slightly more than 60 minutes. The total MR scan time is
also about 60 minutes. For these reasons, we only selected the
hippocampus complete the MRS scan before the effects of
SCP administration returned to baseline. Only differences in
tCho at 30 minutes after SCP injection reached the level of
statistical significance. In our study, the levels of tCho at 3
and 5 mg/kg SCP dose were significantly reduced as
comparing with determinations at the lower doses. In the
microdialysis results, a dose of only 0.5 mg/Kg of SCP was
used to induce changes of ACh and choline levels (36). The
minimum effective dose of SCP is dependent on many exper-
imental conditions—the species/strain, age, the sex of the ro-
dents, the injection method/time interval, and the
monitoring tool (31). Moreover, the microdialysis measured
from extracellular fluid is very sensitive (units, picomoles
per minute), while tCho was quantified by in vivo 1H MRS
from a localized tissue volume (units, millimoles per kilogram
wet weight). We also found that the levels of tCho returned to
normal values at 72 hours after injection at all doses of SCP
administration. This result is good agreement with previous
studies, which showed the recovery from SCP effects after
more than 2 hours after injection (4,25,37).
In addition to ACh, GABA, Glu/Gln, dopamine trans-
porter, and serotonin transporter are frequently identified as
neurotransmitters related to memory (29). Several reports
have addressed the relationship between learning/memory
impairments and glutamatergic neurotransmission (38–41).
The glutamatergic cycle has been related to the cholinergic
system. However, there have been no reports of changes in
Gln-Glu in the SCP-induced model. In our work, the levels
of Glu and Glx were slightly changed at 3 and 5 mg/kg
SCP dose, but the differences were not statistically significant
(P > .05). However, the glutamatergic change may be found
yet using more elaborate works for the detection of amino
acids (Gln, Glu, and Glx). Thus, this observation may warrant
future investigation.1076In conclusion, the present study is the first in vivo assess-
ment of the dose- and time-dependent effects of SCP
administration on the levels of cerebral metabolites. We
observed that high doses of SCP ($3 mg/kg) caused signif-
icant reductions in the concentrations of tCho in the hippo-
campal region using 1H MRS, and these levels recover after
72 hours after injection. Our findings may provide impor-
tant evidence for altered cholinergic activity in the
SCP-induced model for memory impairment. A better
understanding of the interplay between cholinergic neuro-
transmission by 1H MRS may lead to the development of
novel therapeutic approaches for treating memory deficits
and leading to new insights into the mechanisms of memory
and learning and their deficits.ACKNOWLEDGMENTS
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